Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Real Endpoints, Bluebird Bio enter Zynteglo agreement » 05:22
10/04/22
10/04
05:22
10/04/22
05:22
BLUE

Bluebird Bio

$6.13 /

-0.215 (-3.39%)

Real Endpoints announced…

Real Endpoints announced a collaboration with Bluebird bio to provide multiple health plans with access to an outcomes-based agreement for Zynteglo through the Real Endpoints Marketplace. These plans cover nearly 16M individuals across the U.S.; while treatment-dependent beta-thalassemia is a rare disease, together these plans comprise a significant portion of the patient population in the U.S. Zynteglo is currently the only FDA-approved gene therapy for people with beta-thalassemia who require regular red blood cell transfusions. Through a single contract, the plans in RE Marketplace can take immediate advantage of bluebird's innovative agreement, which offers rebates of up to 80% if treatment with Zynteglo does not enable a patient to achieve and maintain transfusion independence in the two years following therapy. RE Marketplace performs all the required analytics and financial reconciliation as an expert, independent third-party. RE Marketplace provides participating plans and manufacturers with end-to-end capabilities for efficient, scalable value-based contracting - and does so with complete financial and data transparency.

ShowHide Related Items >><<
BLUE Bluebird Bio
$6.13 /

-0.215 (-3.39%)

BLUE Bluebird Bio
$6.13 /

-0.215 (-3.39%)

09/27/22 Morgan Stanley
Vertex exa-cel filing timeline 'better than feared,' says Morgan Stanley
08/22/22 William Blair
'Sticker shock' may limit uptake of Bluebird's Zynteglo, says William Blair
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
08/17/22 Piper Sandler
Piper says FDA nod for Bluebird's beta-cel positive for Crispr's exa-cel
BLUE Bluebird Bio
$6.13 /

-0.215 (-3.39%)

BLUE Bluebird Bio
$6.13 /

-0.215 (-3.39%)

BLUE Bluebird Bio
$6.13 /

-0.215 (-3.39%)

BLUE Bluebird Bio
$6.13 /

-0.215 (-3.39%)

Over a week ago
On The Fly
Short Report: Marathon Digital bears skeptical of bottom in stock price » 15:48
09/30/22
09/30
15:48
09/30/22
15:48
MARA

Marathon Digital

$10.94 /

+0.17 (+1.58%)

, RAD

Rite Aid

$5.03 /

-0.035 (-0.69%)

, ASAN

Asana

$22.49 /

+0.23 (+1.03%)

, SPCE

Virgin Galactic

$4.77 /

-0.105 (-2.16%)

, FAZE

FaZe Holdings

$9.45 /

+0.16 (+1.72%)

, BLUE

Bluebird Bio

$6.30 /

+0.58 (+10.14%)

Welcome to this week’s…

ShowHide Related Items >><<
SPCE Virgin Galactic
$4.77 /

-0.105 (-2.16%)

RAD Rite Aid
$5.03 /

-0.035 (-0.69%)

MARA Marathon Digital
$10.94 /

+0.17 (+1.58%)

FAZE FaZe Holdings
$9.45 /

+0.16 (+1.72%)

BLUE Bluebird Bio
$6.30 /

+0.58 (+10.14%)

ASAN Asana
$22.49 /

+0.23 (+1.03%)

MARA Marathon Digital
$10.94 /

+0.17 (+1.58%)

09/23/22 BTIG
Marathon Digital cut to Neutral at BTIG on bankruptcy of its hosting provider
09/23/22 BTIG
Marathon Digital downgraded to Neutral from Buy at BTIG
09/15/22 DA Davidson
Marathon Digital price target lowered to $22 from $30 at DA Davidson
08/23/22 Cowen
Marathon Digital price target raised to $9 from $7 at Cowen
RAD Rite Aid
$5.03 /

-0.035 (-0.69%)

09/30/22 Evercore ISI
Rite Aid removed from 'TAP Outperform' list at Evercore ISI, target cut to $4.50
06/03/22 Deutsche Bank
Rite Aid price target raised to $4 from $2 at Deutsche Bank
04/21/22 Deutsche Bank
Deutsche Bank says 'just stop' with the Rite Aid takeover talk
04/18/22 Deutsche Bank
Rite Aid price target raised to $2 from $1 at Deutsche Bank
ASAN Asana
$22.49 /

+0.23 (+1.03%)

09/23/22 Credit Suisse
Asana initiated with a Neutral at Credit Suisse
09/22/22 MoffettNathanson
Asana initiated with a Market Perform at MoffettNathanson
09/08/22 Citi
Asana price target raised to $24 from $23 at Citi
09/08/22 RBC Capital
Asana price target raised to $15 from $13 at RBC Capital
SPCE Virgin Galactic
$4.77 /

-0.105 (-2.16%)

09/09/22 Bernstein
Virgin Galactic downgraded to Underperform from Market Perform at Bernstein
08/18/22 BofA
Virgin Galactic price target lowered to $5 from $7 at BofA
08/05/22 Truist
Virgin Galactic downgraded to Sell from Hold at Truist
08/05/22 Truist
Virgin Galactic downgraded to Sell from Hold at Truist
FAZE FaZe Holdings
$9.45 /

+0.16 (+1.72%)

BLUE Bluebird Bio
$6.30 /

+0.58 (+10.14%)

09/27/22 Morgan Stanley
Vertex exa-cel filing timeline 'better than feared,' says Morgan Stanley
08/22/22 William Blair
'Sticker shock' may limit uptake of Bluebird's Zynteglo, says William Blair
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
08/17/22 Piper Sandler
Piper says FDA nod for Bluebird's beta-cel positive for Crispr's exa-cel
SPCE Virgin Galactic
$4.77 /

-0.105 (-2.16%)

RAD Rite Aid
$5.03 /

-0.035 (-0.69%)

MARA Marathon Digital
$10.94 /

+0.17 (+1.58%)

BLUE Bluebird Bio
$6.30 /

+0.58 (+10.14%)

ASAN Asana
$22.49 /

+0.23 (+1.03%)

RAD Rite Aid
$5.03 /

-0.035 (-0.69%)

MARA Marathon Digital
$10.94 /

+0.17 (+1.58%)

BLUE Bluebird Bio
$6.30 /

+0.58 (+10.14%)

SPCE Virgin Galactic
$4.77 /

-0.105 (-2.16%)

RAD Rite Aid
$5.03 /

-0.035 (-0.69%)

MARA Marathon Digital
$10.94 /

+0.17 (+1.58%)

FAZE FaZe Holdings
$9.45 /

+0.16 (+1.72%)

BLUE Bluebird Bio
$6.30 /

+0.58 (+10.14%)

ASAN Asana
$22.49 /

+0.23 (+1.03%)

SPCE Virgin Galactic
$4.77 /

-0.105 (-2.16%)

RAD Rite Aid
$5.03 /

-0.035 (-0.69%)

MARA Marathon Digital
$10.94 /

+0.17 (+1.58%)

FAZE FaZe Holdings
$9.45 /

+0.16 (+1.72%)

BLUE Bluebird Bio
$6.30 /

+0.58 (+10.14%)

ASAN Asana
$22.49 /

+0.23 (+1.03%)

Options
Bluebird Bio call volume above normal and directionally bullish » 10:45
09/30/22
09/30
10:45
09/30/22
10:45
BLUE

Bluebird Bio

$6.48 /

+0.76 (+13.29%)

Bullish option flow…

Bullish option flow detected in Bluebird Bio with 3,445 calls trading, 1.8x expected, and implied vol increasing almost 5 points to 125.64%. Oct-22 7.5 calls and Oct-22 10 calls are the most active options, with total volume in those strikes near 2,800 contracts. The Put/Call Ratio is 0.02. Earnings are expected on November 3rd.

ShowHide Related Items >><<
BLUE Bluebird Bio
$6.48 /

+0.76 (+13.29%)

BLUE Bluebird Bio
$6.48 /

+0.76 (+13.29%)

09/27/22 Morgan Stanley
Vertex exa-cel filing timeline 'better than feared,' says Morgan Stanley
08/22/22 William Blair
'Sticker shock' may limit uptake of Bluebird's Zynteglo, says William Blair
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
08/17/22 Piper Sandler
Piper says FDA nod for Bluebird's beta-cel positive for Crispr's exa-cel
BLUE Bluebird Bio
$6.48 /

+0.76 (+13.29%)

BLUE Bluebird Bio
$6.48 /

+0.76 (+13.29%)

BLUE Bluebird Bio
$6.48 /

+0.76 (+13.29%)

BLUE Bluebird Bio
$6.48 /

+0.76 (+13.29%)

Recommendations
Vertex exa-cel filing timeline 'better than feared,' says Morgan Stanley » 11:05
09/27/22
09/27
11:05
09/27/22
11:05
VRTX

Vertex Pharmaceuticals

$289.25 /

+12.59 (+4.55%)

, CRSP

Crispr Therapeutics

$65.17 /

+3.77 (+6.14%)

, BLUE

Bluebird Bio

$5.55 /

+0.405 (+7.87%)

After Vertex…

After Vertex Pharmaceuticals (VRTX) and Crispr Therapeutics (CRSP) announced that Vertex has concluded talks with the FDA and will submit its biologics licensing application for exagamglogene autotemcel, or exa-cel, for rolling review beginning in November and expects to complete the submission by the end of Q1, Morgan Stanley analyst Matthew Harrison called the timeline "better than feared." Investors had worried the U.S. filing may not occur until Q4 of 2023, so today's news is a positive, added Harrison. Given that Bluebird Bio (BLUE) plans to submit its BLA for lovo-cel in sickle cell disease in Q1 of 2023, lovo-cel and exa-cel will likely be reviewed and launched around the same time, which Harrison calls "a relative negative" for Bluebird as it sets-up a more competitive launch. He has an Equal Weight rating and $253 price target on Vertex shares.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$289.25 /

+12.59 (+4.55%)

CRSP Crispr Therapeutics
$65.17 /

+3.77 (+6.14%)

BLUE Bluebird Bio
$5.55 /

+0.405 (+7.87%)

VRTX Vertex Pharmaceuticals
$289.25 /

+12.59 (+4.55%)

08/17/22 Piper Sandler
Piper says FDA nod for Bluebird's beta-cel positive for Crispr's exa-cel
08/16/22 Piper Sandler
Vertex Pharmaceuticals price target raised to $288 from $256 at Piper Sandler
08/05/22 Truist
Global Blood could complement any oncology franchise, says Truist
08/05/22 H.C. Wainwright
Vertex Pharmaceuticals price target raised to $300 from $275 at H.C. Wainwright
CRSP Crispr Therapeutics
$65.17 /

+3.77 (+6.14%)

08/09/22 Stifel
Crispr Therapeutics price target raised to $69 from $55 at Stifel
08/09/22 Credit Suisse
Crispr Therapeutics price target raised to $90 from $74 at Credit Suisse
08/09/22 Barclays
Crispr Therapeutics downgraded to Equal Weight from Overweight at Barclays
BLUE Bluebird Bio
$5.55 /

+0.405 (+7.87%)

08/22/22 William Blair
'Sticker shock' may limit uptake of Bluebird's Zynteglo, says William Blair
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
08/05/22 Barclays
Barclays upgrades Bluebird Bio to Equal Weight, raises price target to $5
VRTX Vertex Pharmaceuticals
$289.25 /

+12.59 (+4.55%)

CRSP Crispr Therapeutics
$65.17 /

+3.77 (+6.14%)

BLUE Bluebird Bio
$5.55 /

+0.405 (+7.87%)

CRSP Crispr Therapeutics
$65.17 /

+3.77 (+6.14%)

BLUE Bluebird Bio
$5.55 /

+0.405 (+7.87%)

VRTX Vertex Pharmaceuticals
$289.25 /

+12.59 (+4.55%)

CRSP Crispr Therapeutics
$65.17 /

+3.77 (+6.14%)

BLUE Bluebird Bio
$5.55 /

+0.405 (+7.87%)

VRTX Vertex Pharmaceuticals
$289.25 /

+12.59 (+4.55%)

CRSP Crispr Therapeutics
$65.17 /

+3.77 (+6.14%)

BLUE Bluebird Bio
$5.55 /

+0.405 (+7.87%)

Options
Largest borrow rate increases among liquid names » 08:45
09/27/22
09/27
08:45
09/27/22
08:45
BLUE

Bluebird Bio

$5.15 /

-0.485 (-8.61%)

, TIGR

UP Fintech

$3.29 /

+0.065 (+2.02%)

, BRCC

BRC Inc.

$7.42 /

-0.03 (-0.40%)

, AKLI

Akili Interactive

$2.58 /

+0.135 (+5.52%)

, BLNK

Blink Charging

$17.54 /

-0.49 (-2.72%)

, DWAC

Digital World Acquisition

$17.60 /

+1.15 (+6.99%)

, CLNN

Clene

$2.93 /

+0.01 (+0.34%)

, MARA

Marathon Digital

$9.62 /

+0.16 (+1.69%)

, IWF

iShares Russell 1000 Growth

$215.22 /

-1.99 (-0.92%)

, SH

ProShares Short S&P500

$16.97 /

+0.185 (+1.10%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Bluebird Bio (BLUE) 13.45% +12.03, UP Fintech Holding Ltd (TIGR) 41.00% +3.11, SilverBox Engaged Merger Corp (BRCC) 35.91% +0.60, Akili Inc (AKLI) 19.54% +0.41, Blink Charging (BLNK) 15.67% +0.30, Digital World Acquisition Corp (DWAC) 37.93% +0.29, Clene (CLNN) 78.75% +0.26, Marathon Patent Group (MARA) 13.69% +0.25, iShares Russell 1000 Growth Index Fund (IWF) 0.75% +0.21, and ProShares Short S&P 500 (SH) 2.66% +0.18.

ShowHide Related Items >><<
TIGR UP Fintech
$3.29 /

+0.065 (+2.02%)

MARA Marathon Digital
$9.62 /

+0.16 (+1.69%)

DWAC Digital World Acquisition
$17.60 /

+1.15 (+6.99%)

CLNN Clene
$2.93 /

+0.01 (+0.34%)

BRCC BRC Inc.
$7.42 /

-0.03 (-0.40%)

BLUE Bluebird Bio
$5.15 /

-0.485 (-8.61%)

BLNK Blink Charging
$17.54 /

-0.49 (-2.72%)

AKLI Akili Interactive
$2.58 /

+0.135 (+5.52%)

BLUE Bluebird Bio
$5.15 /

-0.485 (-8.61%)

08/22/22 William Blair
'Sticker shock' may limit uptake of Bluebird's Zynteglo, says William Blair
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
08/17/22 Piper Sandler
Piper says FDA nod for Bluebird's beta-cel positive for Crispr's exa-cel
08/05/22 Barclays
Barclays upgrades Bluebird Bio to Equal Weight, raises price target to $5
TIGR UP Fintech
$3.29 /

+0.065 (+2.02%)

06/13/22 Daiwa
UP Fintech price target raised to $5.70 from $5.40 at Daiwa
05/19/22 China Renaissance
UP Fintech assumed with Hold from Buy at China Renaissance
12/01/21 Citi
UP Fintech price target lowered to $7.58 from $18.22 at Citi
10/29/21 Alliance Global Partners
MICT could benefit on top China brokers' fallout, says Alliance Global Partners
BRCC BRC Inc.
$7.42 /

-0.03 (-0.40%)

08/23/22 Tigress Financial
BRC Inc. price target raised to $19 from $17 at Tigress Financial
08/12/22 Truist
BRC Inc. price target lowered to $12 from $15 at Truist
08/01/22 Citi
BRC Inc. transferred with Neutral, $10 target at Citi
07/11/22 Citi
BRC Inc. price target lowered to $10 from $13 at Citi
AKLI Akili Interactive
$2.58 /

+0.135 (+5.52%)

09/06/22 Cowen
Akili Interactive initiated with an Outperform at Cowen
BLNK Blink Charging
$17.54 /

-0.49 (-2.72%)

08/16/22 Stifel
Blink Charging price target raised to $23 from $19 at Stifel
06/22/22 Stifel
Blink Charging price target lowered to $19 from $30 at Stifel
06/17/22 B. Riley
B. Riley sees challenges for Blink Charging, starts with Neutral
06/17/22 B. Riley
Blink Charging initiated with a Neutral at B. Riley
DWAC Digital World Acquisition
$17.60 /

+1.15 (+6.99%)

CLNN Clene
$2.93 /

+0.01 (+0.34%)

07/18/22 H.C. Wainwright
Clene initiated with a Buy at H.C. Wainwright
05/02/22 Canaccord
Clene initiated with a Buy at Canaccord
11/03/21 Cantor Fitzgerald
Clene price target lowered to $15 from $24 at Cantor Fitzgerald
11/02/21 Roth Capital
Roth reiterates Buy on Clene after unblinded analysis of CNM-Au8 in ALS trial
MARA Marathon Digital
$9.62 /

+0.16 (+1.69%)

09/23/22 BTIG
Marathon Digital cut to Neutral at BTIG on bankruptcy of its hosting provider
09/23/22 BTIG
Marathon Digital downgraded to Neutral from Buy at BTIG
09/15/22 DA Davidson
Marathon Digital price target lowered to $22 from $30 at DA Davidson
08/23/22 Cowen
Marathon Digital price target raised to $9 from $7 at Cowen
IWF iShares Russell 1000 Growth
$215.22 /

-1.99 (-0.92%)

SH ProShares Short S&P500
$16.97 /

+0.185 (+1.10%)

MARA Marathon Digital
$9.62 /

+0.16 (+1.69%)

CLNN Clene
$2.93 /

+0.01 (+0.34%)

BRCC BRC Inc.
$7.42 /

-0.03 (-0.40%)

BLUE Bluebird Bio
$5.15 /

-0.485 (-8.61%)

BLNK Blink Charging
$17.54 /

-0.49 (-2.72%)

MARA Marathon Digital
$9.62 /

+0.16 (+1.69%)

DWAC Digital World Acquisition
$17.60 /

+1.15 (+6.99%)

CLNN Clene
$2.93 /

+0.01 (+0.34%)

BLUE Bluebird Bio
$5.15 /

-0.485 (-8.61%)

MARA Marathon Digital
$9.62 /

+0.16 (+1.69%)

DWAC Digital World Acquisition
$17.60 /

+1.15 (+6.99%)

CLNN Clene
$2.93 /

+0.01 (+0.34%)

BLUE Bluebird Bio
$5.15 /

-0.485 (-8.61%)

BLNK Blink Charging
$17.54 /

-0.49 (-2.72%)

TIGR UP Fintech
$3.29 /

+0.065 (+2.02%)

MARA Marathon Digital
$9.62 /

+0.16 (+1.69%)

DWAC Digital World Acquisition
$17.60 /

+1.15 (+6.99%)

CLNN Clene
$2.93 /

+0.01 (+0.34%)

BRCC BRC Inc.
$7.42 /

-0.03 (-0.40%)

BLUE Bluebird Bio
$5.15 /

-0.485 (-8.61%)

BLNK Blink Charging
$17.54 /

-0.49 (-2.72%)

AKLI Akili Interactive
$2.58 /

+0.135 (+5.52%)

Hot Stocks
Bluebird Bio names Katherine Breedis interim CFO » 16:21
09/23/22
09/23
16:21
09/23/22
16:21
BLUE

Bluebird Bio

$5.63 /

-0.325 (-5.46%)

In a regulatory filing,…

In a regulatory filing, on September 22, 2022, the board of directors of Bluebird Bio appointed Katherine Breedis to serve as the company's interim Chief Financial Officer and designated Ms. Breedis as the company's principal financial officer and principal accounting officer, succeeding Jason F. Cole, the company's current Chief Strategy and Financial Officer. Breedis' appointment will be effective upon Cole's departure from the company on October 14, 2022. Breedis has served as a Chief Financial Officer Consultant at Danforth Advisors, strategic finance and operations firm with a focus on life sciences companies, since July 2021, where she provides interim chief financial officer and strategic business development consulting services to public and private U.S.-based and international biotechnology companies.

ShowHide Related Items >><<
BLUE Bluebird Bio
$5.63 /

-0.325 (-5.46%)

BLUE Bluebird Bio
$5.63 /

-0.325 (-5.46%)

08/22/22 William Blair
'Sticker shock' may limit uptake of Bluebird's Zynteglo, says William Blair
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
08/17/22 Piper Sandler
Piper says FDA nod for Bluebird's beta-cel positive for Crispr's exa-cel
08/05/22 Barclays
Barclays upgrades Bluebird Bio to Equal Weight, raises price target to $5
BLUE Bluebird Bio
$5.63 /

-0.325 (-5.46%)

BLUE Bluebird Bio
$5.63 /

-0.325 (-5.46%)

BLUE Bluebird Bio
$5.63 /

-0.325 (-5.46%)

BLUE Bluebird Bio
$5.63 /

-0.325 (-5.46%)

Options
Bluebird Bio call volume above normal and directionally bullish » 12:25
09/20/22
09/20
12:25
09/20/22
12:25
BLUE

Bluebird Bio

$6.85 /

+0.925 (+15.61%)

Bullish option flow…

Bullish option flow detected in Bluebird Bio with 9,847 calls trading, 2x expected, and implied vol increasing over 5 points to 125.15%. Oct-22 7.5 calls and Oct-22 12.5 calls are the most active options, with total volume in those strikes near 6,900 contracts. The Put/Call Ratio is 0.10. Earnings are expected on November 3rd.

ShowHide Related Items >><<
BLUE Bluebird Bio
$6.85 /

+0.925 (+15.61%)

BLUE Bluebird Bio
$6.85 /

+0.925 (+15.61%)

08/22/22 William Blair
'Sticker shock' may limit uptake of Bluebird's Zynteglo, says William Blair
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
08/17/22 Piper Sandler
Piper says FDA nod for Bluebird's beta-cel positive for Crispr's exa-cel
08/05/22 Barclays
Barclays upgrades Bluebird Bio to Equal Weight, raises price target to $5
BLUE Bluebird Bio
$6.85 /

+0.925 (+15.61%)

BLUE Bluebird Bio
$6.85 /

+0.925 (+15.61%)

BLUE Bluebird Bio
$6.85 /

+0.925 (+15.61%)

BLUE Bluebird Bio
$6.85 /

+0.925 (+15.61%)

On The Fly
Fly Intel: Pre-market Movers » 08:59
09/19/22
09/19
08:59
09/19/22
08:59
KNBE

KnowBe4

$17.30 /

-1.135 (-6.16%)

, FOXO

FOXO Technologies

$4.15 /

-1.84 (-30.72%)

, BLUE

Bluebird Bio

$6.31 /

-0.79 (-11.13%)

, WIX

Wix.com

$73.71 /

-2.65 (-3.47%)

, TBPH

Theravance Biopharma

$10.07 /

+0.03 (+0.30%)

, AZO

AutoZone

$2,165.63 /

+21.97 (+1.02%)

, EBF

Ennis

$20.22 /

+0.22 (+1.10%)

, VIRI

Virios Therapeutics

$8.73 /

+0.95 (+12.21%)

, TTWO

Take-Two

$124.19 /

-4.405 (-3.43%)

, ADBE

Adobe

$299.50 /

-9.375 (-3.04%)

Check out this morning's…

ShowHide Related Items >><<
WIX Wix.com
$73.71 /

-2.65 (-3.47%)

VIRI Virios Therapeutics
$8.73 /

+0.95 (+12.21%)

TTWO Take-Two
$124.19 /

-4.405 (-3.43%)

TBPH Theravance Biopharma
$10.07 /

+0.03 (+0.30%)

KNBE KnowBe4
$17.30 /

-1.135 (-6.16%)

FOXO FOXO Technologies
$4.15 /

-1.84 (-30.72%)

EBF Ennis
$20.22 /

+0.22 (+1.10%)

BLUE Bluebird Bio
$6.31 /

-0.79 (-11.13%)

AZO AutoZone
$2,165.63 /

+21.97 (+1.02%)

ADBE Adobe
$299.50 /

-9.375 (-3.04%)

KNBE KnowBe4
$17.30 /

-1.135 (-6.16%)

09/14/22 DA Davidson
DA Davidson starts KnowBe4 at Buy on growing market, cross-sell opportunity
09/14/22 DA Davidson
KnowBe4 initiated with a Buy at DA Davidson
08/05/22 Canaccord
KnowBe4 price target lowered to $25 from $28 at Canaccord
07/13/22 Piper Sandler
KnowBe4 price target lowered to $25 from $29 at Piper Sandler
FOXO FOXO Technologies
$4.15 /

-1.84 (-30.72%)

BLUE Bluebird Bio
$6.31 /

-0.79 (-11.13%)

08/22/22 William Blair
'Sticker shock' may limit uptake of Bluebird's Zynteglo, says William Blair
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
08/17/22 Piper Sandler
Piper says FDA nod for Bluebird's beta-cel positive for Crispr's exa-cel
08/05/22 Barclays
Barclays upgrades Bluebird Bio to Equal Weight, raises price target to $5
WIX Wix.com
$73.71 /

-2.65 (-3.47%)

08/11/22 RBC Capital
Wix.com price target raised to $80 from $75 at RBC Capital
07/26/22 Oppenheimer
Wix.com assumed with Perform from Outperform at Oppenheimer
07/14/22 Morgan Stanley
Wix.com price target lowered to $77 from $85 at Morgan Stanley
06/01/22 Evercore ISI
Wix.com removed from 'Tactical Underperform' list at Evercore ISI
TBPH Theravance Biopharma
$10.07 /

+0.03 (+0.30%)

05/23/22 SVB Securities
Theravance Biopharma initiated with an Outperform at SVB Leerink
02/24/22 H.C. Wainwright
Theravance Biopharma price target raised to $12 from $8 at H.C. Wainwright
11/05/21 JPMorgan
Theravance Biopharma upgraded to Neutral from Underweight at JPMorgan
AZO AutoZone
$2,165.63 /

+21.97 (+1.02%)

09/12/22 UBS
AutoZone price target raised to $2,260 from $2,100 at UBS
06/29/22 DA Davidson
O'Reilly Automotive upgraded to Buy from Neutral at DA Davidson
06/27/22 Goldman Sachs
AutoZone upgraded to Buy from Neutral at Goldman Sachs
06/23/22 Citi
Citi adds AutoZone, Thermo Fisher, Ionis to 'Focus List'
EBF Ennis
$20.22 /

+0.22 (+1.10%)

VIRI Virios Therapeutics
$8.73 /

+0.95 (+12.21%)

12/15/21 H.C. Wainwright
Virios Therapeutics initiated with a Buy at H.C. Wainwright
TTWO Take-Two
$124.19 /

-4.405 (-3.43%)

09/19/22 Benchmark
Take-Two hack presents buying opportunity, says Benchmark
09/06/22 Truist
Take-Two price target lowered to $157 from $162 at Truist
09/05/22 Truist
Take-Two price target lowered to $157 from $162 at Truist
09/01/22 BMO Capital
Take-Two price target lowered to $155 from $182 at BMO Capital
ADBE Adobe
$299.50 /

-9.375 (-3.04%)

09/19/22 Wells Fargo
Wells Fargo downgrades Adobe to Equal Weight, lowers price target to $310
09/19/22 Edward Jones
Adobe downgraded to Hold from Buy at Edward Jones
09/19/22 Wells Fargo
Adobe downgraded to Equal Weight from Overweight at Wells Fargo
09/16/22 Evercore ISI
Adobe price target lowered to $350 from $475 at Evercore ISI
WIX Wix.com
$73.71 /

-2.65 (-3.47%)

VIRI Virios Therapeutics
$8.73 /

+0.95 (+12.21%)

TTWO Take-Two
$124.19 /

-4.405 (-3.43%)

TBPH Theravance Biopharma
$10.07 /

+0.03 (+0.30%)

KNBE KnowBe4
$17.30 /

-1.135 (-6.16%)

EBF Ennis
$20.22 /

+0.22 (+1.10%)

BLUE Bluebird Bio
$6.31 /

-0.79 (-11.13%)

AZO AutoZone
$2,165.63 /

+21.97 (+1.02%)

ADBE Adobe
$299.50 /

-9.375 (-3.04%)

  • 11
    Nov
WIX Wix.com
$73.71 /

-2.65 (-3.47%)

TTWO Take-Two
$124.19 /

-4.405 (-3.43%)

BLUE Bluebird Bio
$6.31 /

-0.79 (-11.13%)

AZO AutoZone
$2,165.63 /

+21.97 (+1.02%)

ADBE Adobe
$299.50 /

-9.375 (-3.04%)

WIX Wix.com
$73.71 /

-2.65 (-3.47%)

TTWO Take-Two
$124.19 /

-4.405 (-3.43%)

TBPH Theravance Biopharma
$10.07 /

+0.03 (+0.30%)

KNBE KnowBe4
$17.30 /

-1.135 (-6.16%)

BLUE Bluebird Bio
$6.31 /

-0.79 (-11.13%)

AZO AutoZone
$2,165.63 /

+21.97 (+1.02%)

ADBE Adobe
$299.50 /

-9.375 (-3.04%)

TTWO Take-Two
$124.19 /

-4.405 (-3.43%)

BLUE Bluebird Bio
$6.31 /

-0.79 (-11.13%)

AZO AutoZone
$2,165.63 /

+21.97 (+1.02%)

ADBE Adobe
$299.50 /

-9.375 (-3.04%)

Hot Stocks
Bluebird receives FDA accelerated approval for SKYSONA for early, active CALD » 15:53
09/18/22
09/18
15:53
09/18/22
15:53
BLUE

Bluebird Bio

$6.31 /

-0.79 (-11.13%)

Bluebird Bio announced…

Bluebird Bio announced the U.S. Food and Drug Administration has granted Accelerated Approval of SKYSONA, also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy. The company also confirmed that the previous clinical hold on the eli-cel clinical development program has been lifted. CALD is a rare, progressive, neurodegenerative disease that primarily affects young boys and causes irreversible, devastating neurologic decline, including major functional disabilities such as loss of communication, cortical blindness, requirement for tube feeding, total incontinence, wheelchair dependence, or complete loss of voluntary movement. Nearly half of patients who do not receive treatment die within five years of symptom onset. Prior to the approval of SKYSONA treatment, effective options were limited to allogeneic hematopoietic stem cell transplant, which is associated with the risk of serious potential complications including death, that can increase dramatically in patients without a human leukocyte antigen matched donor. As a condition of the SKYSONA Accelerated Approval, bluebird has agreed to provide confirmatory long-term clinical data to the FDA. bluebird anticipates that this will include data from the ongoing long-term follow-up study, which follows patients treated in clinical trials for 15 years, and from commercially treated patients. Bluebird anticipates that commercial product will be available by the end of 2022 through a limited number of Qualified Treatment Centers in the United States, including Boston Children's Hospital and Children's Hospital of Philadelphia. Bluebird has set the wholesale acquisition cost of SKYSONA in the U.S. at $3.0M. The SKYSONA Biologics License Application was reviewed by the U.S. FDA under Priority Review, and bluebird received a rare pediatric priority review voucher upon approval. SKYSONA was previously granted Orphan Drug designation, Rare Pediatric Disease designation, and Breakthrough Therapy designation.

ShowHide Related Items >><<
BLUE Bluebird Bio
$6.31 /

-0.79 (-11.13%)

BLUE Bluebird Bio
$6.31 /

-0.79 (-11.13%)

08/22/22 William Blair
'Sticker shock' may limit uptake of Bluebird's Zynteglo, says William Blair
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
08/17/22 Piper Sandler
Piper says FDA nod for Bluebird's beta-cel positive for Crispr's exa-cel
08/05/22 Barclays
Barclays upgrades Bluebird Bio to Equal Weight, raises price target to $5
BLUE Bluebird Bio
$6.31 /

-0.79 (-11.13%)

BLUE Bluebird Bio
$6.31 /

-0.79 (-11.13%)

BLUE Bluebird Bio
$6.31 /

-0.79 (-11.13%)

BLUE Bluebird Bio
$6.31 /

-0.79 (-11.13%)

On The Fly
What You Missed On Wall Street On Monday » 16:21
09/12/22
09/12
16:21
09/12/22
16:21
DIS

Disney

$116.40 /

+1.2 (+1.04%)

, JPM

JPMorgan

$120.62 /

+1.355 (+1.14%)

, TWTR

Twitter

$41.49 /

-0.72 (-1.71%)

, BMY

Bristol-Myers

$72.38 /

+2.21 (+3.15%)

, GE

General Electric

$75.34 /

+1.27 (+1.71%)

, CVNA

Carvana

$42.26 /

+5.68 (+15.53%)

, ADBE

Adobe

$396.35 /

+1.67 (+0.42%)

, RBLX

Roblox

$46.57 /

+1.06 (+2.33%)

, AAPL

Apple

$163.43 /

+6.08 (+3.86%)

, OXY

Occidental Petroleum

$66.81 /

+1.195 (+1.82%)

, AMZN

Amazon.com

$136.47 /

+3.205 (+2.40%)

, MSFT

Microsoft

$266.67 /

+2.21 (+0.84%)

, GS

Goldman Sachs

$342.90 /

+2.66 (+0.78%)

, KKR

KKR

$52.69 /

+1.18 (+2.29%)

, INTC

Intel

$31.57 /

+0.11 (+0.35%)

, SYF

Synchrony

$34.30 /

+0.885 (+2.65%)

, PYPL

PayPal

$97.66 /

+1.39 (+1.44%)

, PNT

Point Biopharma

$10.29 /

+1.68 (+19.51%)

, APA

APA Corp.

$40.00 /

+1.92 (+5.04%)

, AMGN

Amgen

$237.53 /

-10.14 (-4.09%)

, LTHM

Livent

$33.56 /

-0.9 (-2.61%)

, BLUE

Bluebird Bio

$7.31 /

+0.165 (+2.31%)

, AKTS

Akoustis

$3.97 /

-0.46 (-10.38%)

, SGMA

Sigmatron International

$6.86 /

+0.09 (+1.33%)

, RCAT

Red Cat

$2.22 /

-0.23 (-9.39%)

, QSR

Restaurant Brands

$61.79 /

+0.9 (+1.48%)

, ORCL

Oracle

$77.17 /

+1.17 (+1.54%)

Get caught up quickly on…

ShowHide Related Items >><<
TWTR Twitter
$41.49 /

-0.72 (-1.71%)

SYF Synchrony
$34.30 /

+0.885 (+2.65%)

SGMA Sigmatron International
$6.86 /

+0.09 (+1.33%)

RCAT Red Cat
$2.22 /

-0.23 (-9.39%)

RBLX Roblox
$46.57 /

+1.06 (+2.33%)

QSR Restaurant Brands
$61.79 /

+0.9 (+1.48%)

PYPL PayPal
$97.66 /

+1.39 (+1.44%)

PNT Point Biopharma
$10.29 /

+1.68 (+19.51%)

OXY Occidental Petroleum
$66.81 /

+1.195 (+1.82%)

ORCL Oracle
$77.17 /

+1.17 (+1.54%)

MSFT Microsoft
$266.67 /

+2.21 (+0.84%)

LTHM Livent
$33.56 /

-0.9 (-2.61%)

KKR KKR
$52.69 /

+1.18 (+2.29%)

JPM JPMorgan
$120.62 /

+1.355 (+1.14%)

INTC Intel
$31.57 /

+0.11 (+0.35%)

GS Goldman Sachs
$342.90 /

+2.66 (+0.78%)

GE General Electric
$75.34 /

+1.27 (+1.71%)

DIS Disney
$116.40 /

+1.2 (+1.04%)

CVNA Carvana
$42.26 /

+5.68 (+15.53%)

BMY Bristol-Myers
$72.38 /

+2.21 (+3.15%)

BLUE Bluebird Bio
$7.31 /

+0.165 (+2.31%)

APA APA Corp.
$40.00 /

+1.92 (+5.04%)

AMZN Amazon.com
$136.47 /

+3.205 (+2.40%)

AMGN Amgen
$237.53 /

-10.14 (-4.09%)

AKTS Akoustis
$3.97 /

-0.46 (-10.38%)

ADBE Adobe
$396.35 /

+1.67 (+0.42%)

AAPL Apple
$163.43 /

+6.08 (+3.86%)

DIS Disney
$116.40 /

+1.2 (+1.04%)

08/22/22 Evercore ISI
Evercore says Apple getting NFL Sunday Ticket rights makes sense
08/11/22 Credit Suisse
Disney price target lowered to $157 from $170 at Credit Suisse
08/11/22 JPMorgan
Disney price target lowered to $160 from $175 at JPMorgan
08/11/22 KeyBanc
Disney price target raised to $154 from $131 at KeyBanc
JPM JPMorgan
$120.62 /

+1.355 (+1.14%)

09/12/22 Deutsche Bank
JPMorgan price target lowered to $155 from $174 at Deutsche Bank
07/18/22 Berenberg
JPMorgan upgraded to Hold from Sell at Berenberg
07/15/22 RBC Capital
JPMorgan price target lowered to $130 from $155 at RBC Capital
07/15/22 Evercore ISI
JPMorgan price target lowered to $125 from $135 at Evercore ISI
TWTR Twitter
$41.49 /

-0.72 (-1.71%)

08/24/22 Gordon Haskett
Twitter whistleblower has no 'smoking gun,' says Gordon Haskett
08/24/22 Rosenblatt
Rosenblatt downgrades Twitter on risk of Musk using whistleblower suit
08/24/22 Rosenblatt
Twitter downgraded to Neutral from Buy at Rosenblatt
08/10/22 Gordon Haskett
Tesla sale shows Musk knows must come up with Twitter money, says Gordon Haskett
BMY Bristol-Myers
$72.38 /

+2.21 (+3.15%)

09/12/22 Evercore ISI
Evercore expecting 'strong move' in Ventyx after Deucravacitinib label surprise
09/12/22 Morgan Stanley
Bristol-Myers' label for Deucrava better than expected, says Morgan Stanley
09/12/22 BMO Capital
Bristol-Myers price target raised to $94 from $92 at BMO Capital
09/12/22 Oppenheimer
Ventyx Biosciences price target raised to $65 from $40 at Oppenheimer
GE General Electric
$75.34 /

+1.27 (+1.71%)

08/16/22 Bernstein
General Electric resumed with an Outperform at Bernstein
07/27/22 Morgan Stanley
GE 'not out of the woods,' but 'properly reset,' says Morgan Stanley
07/27/22 Deutsche Bank
General Electric price target lowered to $88 from $90 at Deutsche Bank
07/18/22 Cowen
Cowen believes Aerospace and Defense quarterly results to be mixed
CVNA Carvana
$42.26 /

+5.68 (+15.53%)

09/12/22 Piper Sandler
Carvana upgraded to Overweight from Neutral at Piper Sandler
08/25/22 Wedbush
Carvana tapping ABS market a 'good sign,' says Wedbush
08/18/22 Argus
Argus starts Carvana at Hold, sees the stock as fairly valued
08/18/22 Argus
Carvana initiated with a Hold at Argus
ADBE Adobe
$396.35 /

+1.67 (+0.42%)

09/13/22 BMO Capital
Adobe cut to Market Perform at BMO Capital on reduced Creative Cloud demand
09/13/22 BMO Capital
Adobe downgraded to Market Perform from Outperform at BMO Capital
09/12/22 Mizuho
Adobe downgraded to Neutral from Buy at Mizuho
09/08/22 Barclays
Adobe price target lowered to $440 from $445 at Barclays
RBLX Roblox
$46.57 /

+1.06 (+2.33%)

09/13/22 Morgan Stanley
Roblox will face challenges executing on ads opportunity, says Morgan Stanley
09/12/22 Cowen
Roblox initiated with an Underperform at Cowen
08/16/22 Wolfe Research
Roblox initiated with a Peer Perform at Wolfe Research
08/12/22 Deutsche Bank
Roblox price target raised to $52 from $45 at Deutsche Bank
AAPL Apple
$163.43 /

+6.08 (+3.86%)

09/13/22 Evercore ISI
Apple iPhone delivery data points to robust demand, says Evercore ISI
09/12/22 BofA
Early iPhone pre-order data positive for Apple, says BofA
09/12/22 Wedbush
Apple iPhone 14 pre-order demand looks robust, says Wedbush
09/09/22 JPMorgan
Verizon iPhone promos not as aggressive as AT&T, says JPMorgan
OXY Occidental Petroleum
$66.81 /

+1.195 (+1.82%)

09/12/22 Citi
Occidental downgraded on 'modest upside' after outperformance at Citi
09/12/22 Citi
Occidental Petroleum downgraded to Neutral from Buy at Citi
09/12/22 Piper Sandler
Occidental Petroleum price target lowered to $92 from $93 at Piper Sandler
09/06/22 Morgan Stanley
Occidental Petroleum price target raised to $76 from $70 at Morgan Stanley
AMZN Amazon.com
$136.47 /

+3.205 (+2.40%)

09/12/22 DA Davidson
Amazon.com may be more open to M&A under CEO Jassy, says DA Davidson
08/29/22 Citi
Amazon deal for Electronic Arts would bring regulatory risks, says Citi
08/26/22 Benchmark
EA could be valued at $188 per share in competitive process, says Benchmark
08/26/22 Craig-Hallum
Plug Power price target raised to $38 from $31 at Craig-Hallum
MSFT Microsoft
$266.67 /

+2.21 (+0.84%)

09/12/22 KeyBanc
RingCentral initiated with an Overweight at KeyBanc
08/29/22 BMO Capital
Okta price target lowered to $110 from $125 at BMO Capital
08/16/22 Citi
Zoom Video downgraded to Sell from Neutral at Citi
GS Goldman Sachs
$342.90 /

+2.66 (+0.78%)

09/12/22 Deutsche Bank
Goldman Sachs price target lowered to $370 from $430 at Deutsche Bank
09/06/22 Odeon Capital
Goldman Sachs downgraded to Sell from Hold at Odeon Capital
07/19/22 BMO Capital
Goldman Sachs price target lowered to $461 from $475 at BMO Capital
07/19/22 Barclays
Goldman Sachs price target lowered to $450 from $505 at Barclays
KKR KKR
$52.69 /

+1.18 (+2.29%)

08/12/22 Deutsche Bank
KKR price target raised to $68 from $65 at Deutsche Bank
07/13/22 Deutsche Bank
KKR price target lowered to $66 from $79 at Deutsche Bank
07/12/22 JMP Securities
KKR price target lowered to $80 from $85 at JMP Securities
07/11/22 Piper Sandler
KKR price target lowered to $80 from $86 at Piper Sandler
INTC Intel
$31.57 /

+0.11 (+0.35%)

09/08/22 Deutsche Bank
Intel price target lowered to $35 from $38 at Deutsche Bank
09/07/22 Stifel
Stifel starts Intel at Hold with turnaround in 'early innings'
09/07/22 Stifel
Stifel starts AMD at Buy with $122 price target
09/07/22 Stifel
Intel initiated with a Hold at Stifel
SYF Synchrony
$34.30 /

+0.885 (+2.65%)

07/19/22 Stephens
Synchrony price target raised to $35 from $29 at Stephens
07/13/22 Wells Fargo
Synchrony downgraded to Equal Weight at Wells Fargo on cautious macro view
07/13/22 Wells Fargo
Synchrony downgraded to Equal Weight from Overweight at Wells Fargo
07/12/22 Morgan Stanley
Synchrony price target lowered to $31 from $40 at Morgan Stanley
PYPL PayPal
$97.66 /

+1.39 (+1.44%)

09/12/22 Barclays
PayPal price target lowered to $125 from $131 at Barclays
09/12/22 Deutsche Bank
PayPal price target raised to $140 from $114 at Deutsche Bank
08/31/22 BofA
BofA upgrades PayPal to Buy on attractive risk/reward into initiatives
08/31/22 BofA
PayPal upgraded to Buy from Neutral at BofA
PNT Point Biopharma
$10.29 /

+1.68 (+19.51%)

09/12/22 Guggenheim
Point Biopharma price target raised to $22 from $20 at Guggenheim
09/11/22 Piper Sandler
Point Biopharma price target raised to $19 from $14 at Piper Sandler
09/07/22 Jefferies
Point Biopharma selloff on ESMO abstract release 'unwarranted,' says Jefferies
09/06/22 JonesTrading
Point Biopharma initiated with a Buy at JonesTrading
APA APA Corp.
$40.00 /

+1.92 (+5.04%)

09/12/22 Citi
Citi opens '90-day Catalyst Watch' in APA into well results
09/12/22 Citi
APA Corp. upgraded to Buy from Neutral at Citi
08/31/22 Barclays
APA Corp. price target lowered to $53 from $55 at Barclays
08/26/22 MKM Partners
APA Corp. price target raised to $50 from $45 at MKM Partners
AMGN Amgen
$237.53 /

-10.14 (-4.09%)

08/08/22 Piper Sandler
Amgen combo data for Lumakras disappoints, says Piper Sandler
08/08/22 JMP Securities
Mirati Therapeutics price target raised to $110 from $90 at JMP Securities
08/05/22 RBC Capital
Amgen price target raised to $236 from $224 at RBC Capital
08/05/22 Piper Sandler
Amgen price target raised to $265 from $260 at Piper Sandler
LTHM Livent
$33.56 /

-0.9 (-2.61%)

09/12/22 Vertical Research
Livent downgraded to Hold from Buy at Vertical Research
08/08/22 CICC
Livent initiated with an Outperform at CICC
07/06/22 Deutsche Bank
Livent price target lowered to $24 from $29 at Deutsche Bank
05/17/22 Deutsche Bank
Livent initiated with a Hold at Deutsche Bank
BLUE Bluebird Bio
$7.31 /

+0.165 (+2.31%)

08/22/22 William Blair
'Sticker shock' may limit uptake of Bluebird's Zynteglo, says William Blair
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
08/17/22 Piper Sandler
Piper says FDA nod for Bluebird's beta-cel positive for Crispr's exa-cel
08/05/22 Barclays
Barclays upgrades Bluebird Bio to Equal Weight, raises price target to $5
AKTS Akoustis
$3.97 /

-0.46 (-10.38%)

09/13/22 Piper Sandler
Akoustis price target lowered to $5 from $7 at Piper Sandler
05/17/22 Piper Sandler
Piper moves to 'more positive stance' on semiconductor stocks
05/02/22 Piper Sandler
Akoustis price target lowered to $7 from $10.50 at Piper Sandler
02/01/22 Craig-Hallum
Akoustis price target lowered to $12 from $18 at Craig-Hallum
SGMA Sigmatron International
$6.86 /

+0.09 (+1.33%)

RCAT Red Cat
$2.22 /

-0.23 (-9.39%)

QSR Restaurant Brands
$61.79 /

+0.9 (+1.48%)

09/07/22 Bernstein
Bernstein starts Restaurant Brands at Market Perform with $64 price target
09/07/22 Bernstein
Restaurant Brands initiated with a Market Perform at Bernstein
08/30/22 Citi
Bill could pressure California limited service restaurants, says Citi
08/09/22 Argus
Restaurant Brands upgraded to Buy at Argus on earnings upside
ORCL Oracle
$77.17 /

+1.17 (+1.54%)

09/13/22 Evercore ISI
Oracle price target raised to $87 from $78 at Evercore ISI
09/13/22 BMO Capital
Oracle price target raised to $90 from $86 at BMO Capital
09/13/22 JPMorgan
Oracle price target raised to $84 from $82 at JPMorgan
09/13/22 Deutsche Bank
Oracle reported 'very solid' Q1 results, says Deutsche Bank
TWTR Twitter
$41.49 /

-0.72 (-1.71%)

SYF Synchrony
$34.30 /

+0.885 (+2.65%)

SGMA Sigmatron International
$6.86 /

+0.09 (+1.33%)

RCAT Red Cat
$2.22 /

-0.23 (-9.39%)

RBLX Roblox
$46.57 /

+1.06 (+2.33%)

QSR Restaurant Brands
$61.79 /

+0.9 (+1.48%)

PYPL PayPal
$97.66 /

+1.39 (+1.44%)

PNT Point Biopharma
$10.29 /

+1.68 (+19.51%)

OXY Occidental Petroleum
$66.81 /

+1.195 (+1.82%)

ORCL Oracle
$77.17 /

+1.17 (+1.54%)

MSFT Microsoft
$266.67 /

+2.21 (+0.84%)

LTHM Livent
$33.56 /

-0.9 (-2.61%)

KKR KKR
$52.69 /

+1.18 (+2.29%)

JPM JPMorgan
$120.62 /

+1.355 (+1.14%)

INTC Intel
$31.57 /

+0.11 (+0.35%)

GS Goldman Sachs
$342.90 /

+2.66 (+0.78%)

GE General Electric
$75.34 /

+1.27 (+1.71%)

DIS Disney
$116.40 /

+1.2 (+1.04%)

CVNA Carvana
$42.26 /

+5.68 (+15.53%)

BMY Bristol-Myers
$72.38 /

+2.21 (+3.15%)

BLUE Bluebird Bio
$7.31 /

+0.165 (+2.31%)

APA APA Corp.
$40.00 /

+1.92 (+5.04%)

AMZN Amazon.com
$136.47 /

+3.205 (+2.40%)

AMGN Amgen
$237.53 /

-10.14 (-4.09%)

AKTS Akoustis
$3.97 /

-0.46 (-10.38%)

ADBE Adobe
$396.35 /

+1.67 (+0.42%)

AAPL Apple
$163.43 /

+6.08 (+3.86%)

  • 22
    Apr
TWTR Twitter
$41.49 /

-0.72 (-1.71%)

SYF Synchrony
$34.30 /

+0.885 (+2.65%)

RBLX Roblox
$46.57 /

+1.06 (+2.33%)

QSR Restaurant Brands
$61.79 /

+0.9 (+1.48%)

PYPL PayPal
$97.66 /

+1.39 (+1.44%)

OXY Occidental Petroleum
$66.81 /

+1.195 (+1.82%)

ORCL Oracle
$77.17 /

+1.17 (+1.54%)

MSFT Microsoft
$266.67 /

+2.21 (+0.84%)

KKR KKR
$52.69 /

+1.18 (+2.29%)

JPM JPMorgan
$120.62 /

+1.355 (+1.14%)

INTC Intel
$31.57 /

+0.11 (+0.35%)

GS Goldman Sachs
$342.90 /

+2.66 (+0.78%)

GE General Electric
$75.34 /

+1.27 (+1.71%)

DIS Disney
$116.40 /

+1.2 (+1.04%)

CVNA Carvana
$42.26 /

+5.68 (+15.53%)

BMY Bristol-Myers
$72.38 /

+2.21 (+3.15%)

BLUE Bluebird Bio
$7.31 /

+0.165 (+2.31%)

AMZN Amazon.com
$136.47 /

+3.205 (+2.40%)

AMGN Amgen
$237.53 /

-10.14 (-4.09%)

AAPL Apple
$163.43 /

+6.08 (+3.86%)

TWTR Twitter
$41.49 /

-0.72 (-1.71%)

SYF Synchrony
$34.30 /

+0.885 (+2.65%)

QSR Restaurant Brands
$61.79 /

+0.9 (+1.48%)

PYPL PayPal
$97.66 /

+1.39 (+1.44%)

OXY Occidental Petroleum
$66.81 /

+1.195 (+1.82%)

ORCL Oracle
$77.17 /

+1.17 (+1.54%)

MSFT Microsoft
$266.67 /

+2.21 (+0.84%)

LTHM Livent
$33.56 /

-0.9 (-2.61%)

KKR KKR
$52.69 /

+1.18 (+2.29%)

JPM JPMorgan
$120.62 /

+1.355 (+1.14%)

INTC Intel
$31.57 /

+0.11 (+0.35%)

GS Goldman Sachs
$342.90 /

+2.66 (+0.78%)

GE General Electric
$75.34 /

+1.27 (+1.71%)

DIS Disney
$116.40 /

+1.2 (+1.04%)

CVNA Carvana
$42.26 /

+5.68 (+15.53%)

BMY Bristol-Myers
$72.38 /

+2.21 (+3.15%)

BLUE Bluebird Bio
$7.31 /

+0.165 (+2.31%)

APA APA Corp.
$40.00 /

+1.92 (+5.04%)

AMZN Amazon.com
$136.47 /

+3.205 (+2.40%)

AMGN Amgen
$237.53 /

-10.14 (-4.09%)

AKTS Akoustis
$3.97 /

-0.46 (-10.38%)

AAPL Apple
$163.43 /

+6.08 (+3.86%)

TWTR Twitter
$41.49 /

-0.72 (-1.71%)

SYF Synchrony
$34.30 /

+0.885 (+2.65%)

RCAT Red Cat
$2.22 /

-0.23 (-9.39%)

RBLX Roblox
$46.57 /

+1.06 (+2.33%)

PYPL PayPal
$97.66 /

+1.39 (+1.44%)

OXY Occidental Petroleum
$66.81 /

+1.195 (+1.82%)

ORCL Oracle
$77.17 /

+1.17 (+1.54%)

MSFT Microsoft
$266.67 /

+2.21 (+0.84%)

LTHM Livent
$33.56 /

-0.9 (-2.61%)

KKR KKR
$52.69 /

+1.18 (+2.29%)

JPM JPMorgan
$120.62 /

+1.355 (+1.14%)

INTC Intel
$31.57 /

+0.11 (+0.35%)

GS Goldman Sachs
$342.90 /

+2.66 (+0.78%)

GE General Electric
$75.34 /

+1.27 (+1.71%)

DIS Disney
$116.40 /

+1.2 (+1.04%)

CVNA Carvana
$42.26 /

+5.68 (+15.53%)

BMY Bristol-Myers
$72.38 /

+2.21 (+3.15%)

BLUE Bluebird Bio
$7.31 /

+0.165 (+2.31%)

APA APA Corp.
$40.00 /

+1.92 (+5.04%)

AMZN Amazon.com
$136.47 /

+3.205 (+2.40%)

AMGN Amgen
$237.53 /

-10.14 (-4.09%)

ADBE Adobe
$396.35 /

+1.67 (+0.42%)

AAPL Apple
$163.43 /

+6.08 (+3.86%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.